Abstract
Colistin is an important antibiotic against multidrug-resistant (MDR) Gram-negative bacteria (GNB), particularly Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii. Although it is an old antibiotic, Colistin has emerged as an important agent in the treatment of GNB infections, especially those caused by MDR pathogens in hospitalised patients. Limited therapeutic option against Carbapenem-resistant Gram-negative bacilli (E. coli, Klebsiella, Pseudomonas and Acinetobacter) is one of the major problems in clinical practice. The current review discusses the pharmacology, toxicity, drug resistance, importance of therapeutic drug level monitoring and cost of one of the most important antibiotics in the current practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
